Literature DB >> 25717024

Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.

Ju Young Kim1, Han Sang Park1, Si Yeol Kim2.   

Abstract

PURPOSE: To investigate the short-term efficacy of subthreshold micropulse yellow laser photocoagulation in the treatment of chronic central serous chorioretinopathy (CSC).
METHODS: A retrospective case series study was performed from April 2012 to June 2014 at Nune Eye Hospital. A total of ten eyes of ten chronic or chronic recurrent CSC patients received subthreshold micropulse yellow laser photocoagulation with a 15 % duty cycle at a reduced energy level from the micropulse laser test burn. Laser exposure time was 20 ms, and the spot diameter was 100 μm. Patients were followed up at the authors' hospital for at least 3 months.
RESULTS: Mean age of patients was 43.9 years. The baseline best-corrected visual acuity was 0.21 ± 0.21 logarithm of the minimum angle of resolution (logMAR), which was improved to 0.055 ± 0.093 logMAR (p = 0.020) at the  3-month follow-up and 0.035 ± 0.063 logMAR (p = 0.012) at final follow-up. Central macular thickness at baseline was 349.2 ± 53.2 μm, which was changed to 250.7 ± 28.8 μm (p = 0.009) at the 3-month follow-up and 261.2 ± 38.31 μm (p = 0.009) at final follow-up.
CONCLUSIONS: Subthreshold micropulse yellow laser photocoagulation showed short-term efficacy in treating chronic CSC without retinal damage. However, prospective, randomized, and comparative large-scale studies are needed to evaluate the efficacy and safety of this treatment.

Entities:  

Keywords:  Central serous chorioretinopathy; Subthreshold micropulse yellow laser photocoagulation

Mesh:

Year:  2015        PMID: 25717024     DOI: 10.1007/s00417-015-2965-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  37 in total

Review 1.  Decreasing retinal photocoagulation damage: principles and techniques.

Authors:  M A Mainster
Journal:  Semin Ophthalmol       Date:  1999-12       Impact factor: 1.975

2.  Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.

Authors:  Ozgur Artunay; Erdal Yuzbasioglu; Rifat Rasier; Alper Sengul; Halil Bahcecioglu
Journal:  Curr Eye Res       Date:  2010-02       Impact factor: 2.424

3.  A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.

Authors:  So Hyun Bae; Jang Won Heo; Cinoo Kim; Tae Wan Kim; Joo Yong Lee; Su Jeong Song; Tae Kwann Park; Sang Woong Moon; Hum Chung
Journal:  Am J Ophthalmol       Date:  2011-07-13       Impact factor: 5.258

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study.

Authors:  P Lanzetta; F Furlan; L Morgante; D Veritti; F Bandello
Journal:  Eur J Ophthalmol       Date:  2008 Nov-Dec       Impact factor: 2.597

6.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

7.  Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage.

Authors:  San-Ni Chen; Jiunn-Feng Hwang; Li-Fang Tseng; Chun-Ju Lin
Journal:  Ophthalmology       Date:  2008-12       Impact factor: 12.079

8.  Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy.

Authors:  F Ricci; F Missiroli; L Cerulli
Journal:  Eur J Ophthalmol       Date:  2004 Jan-Feb       Impact factor: 2.597

9.  Micropulse diode laser photocoagulation for central serous chorio-retinopathy.

Authors:  Bhaskar Gupta; Mohammed Elagouz; Dominic McHugh; Victor Chong; Sobha Sivaprasad
Journal:  Clin Exp Ophthalmol       Date:  2009-11       Impact factor: 4.207

10.  Digital indocyanine green videoangiography of central serous chorioretinopathy.

Authors:  D R Guyer; L A Yannuzzi; J S Slakter; J A Sorenson; A Ho; D Orlock
Journal:  Arch Ophthalmol       Date:  1994-08
View more
  20 in total

1.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

2.  A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy.

Authors:  Lijun Zhou; Victor Chong; Kunbei Lai; Chuangxin Huang; Fabao Xu; Yajun Gong; Maimaitiaili Youlidaxi; Tao Li; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2019-02-02       Impact factor: 3.161

3.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

4.  Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy.

Authors:  Mehmed Uğur Işık; Mehmet Fatih Kağan Değirmenci; Ayhan Sağlık
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

5.  Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.

Authors:  Yang Jae Kim; Si Yeol Kim; Seungmin Ha; Daruchi Moon; San Seong; Oh Woong Kwon; Han Sang Park
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

6.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

Review 7.  Pachychoroid disease spectrum: review article.

Authors:  Thiago José Muniz Machado Mazzeo; Henrique Monteiro Leber; Allan Gomes da Silva; Raimunda Cristina Mendonça Freire; Gabriel Castilho Sandoval Barbosa; Guilherme Garcia Criado; Gabriel Almeida Veiga Jacob; Cleide Guimarães Machado; André Marcelo Vieira Gomes
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-14       Impact factor: 3.117

8.  Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses.

Authors:  Camila Q Felipe; Ana Luiza Biancardi; Vinicius T Civile; Nelson Carvas Junior; Pedro D Serracarbassa; Marcia K Koike
Journal:  Int J Retina Vitreous       Date:  2022-06-07

9.  Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity.

Authors:  Sezen Akkaya; Banu Açıkalın; Yusuf Emre Doğan; Fatih Çoban
Journal:  Int J Ophthalmol       Date:  2020-10-18       Impact factor: 1.645

10.  Application of subthreshold laser therapy in retinal diseases: a review.

Authors:  Spencer M Moore; Daniel L Chao
Journal:  Expert Rev Ophthalmol       Date:  2018-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.